Collegium Pharmaceutical (COLL)
(Delayed Data from NSDQ)
$37.79 USD
-0.42 (-1.10%)
Updated Sep 24, 2024 04:00 PM ET
After-Market: $37.78 -0.01 (-0.03%) 7:58 PM ET
2-Buy of 5 2
A Value A Growth F Momentum A VGM
Brokerage Reports
Collegium Pharmaceutical, Inc. [COLL]
Reports for Purchase
Showing records 1 - 20 ( 92 total )
Company: Collegium Pharmaceutical, Inc.
Industry: Medical - Drugs
Trigger Pulled on Diversifying Deal; With That and More Confidence in Base Biz Durability, Upgrade to Buy; PT Up to $47
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Collegium Pharmaceutical, Inc.
Industry: Medical - Drugs
Company: Collegium Pharmaceutical, Inc.
Industry: Medical - Drugs
Optimized Entry and Exit Levels for COLL 112123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Collegium Pharmaceutical, Inc.
Industry: Medical - Drugs
2Q Light Revs, But Reiterated Guidance; Accelerated Stock Repurchase Signals Management Confidence; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Collegium Pharmaceutical, Inc.
Industry: Medical - Drugs
Record 1Q as Expected; We Get the Sense Long-Sought Diversifying Biz Dev is Closer
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Collegium Pharmaceutical, Inc.
Industry: Medical - Drugs
Guidance Achievable Without Rx Growth, But We?d Like to See Revived Volume Trajectory For Longer Term Confidence
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Collegium Pharmaceutical, Inc.
Industry: Medical - Drugs
Strong Preliminary 4Q Results; Opportunistic Favorable Debt Balance Sheet Bolstering
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Collegium Pharmaceutical, Inc.
Industry: Medical - Drugs
First-Time 2023 Guide Beats Estimates, Reflecting Major Xtampza ER Economics Boost
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Collegium Pharmaceutical, Inc.
Industry: Medical - Drugs
Solid 3Q Albeit Upside Boosted by One-Offs; Renegotiated Xtampza Contracts Tee Up 2023 Revenue Jump; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Collegium Pharmaceutical, Inc.
Industry: Medical - Drugs
We See Stock Stuck Until Rx Trends and Xtampza Economics Improve; Can?t Hang Thesis on M&A Alone; Downgrade to Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Collegium Pharmaceutical, Inc.
Industry: Medical - Drugs
1Q22: A Welcome Clean Start to 2022; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Collegium Pharmaceutical, Inc.
Industry: Medical - Drugs
Solid, and Likely Conservative, First-Time 2022 Guide Post BDSI Acquisition
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Collegium Pharmaceutical, Inc.
Industry: Medical - Drugs
Muddled 4Q Ending Challenging Year, But Stand-Alone Guidance Looks Solid; BDSI Deal Close On Tap; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Collegium Pharmaceutical, Inc.
Industry: Medical - Drugs
Collegium Snares Its Commercial, High-Synergy Takeout Target in BDSI; Raise Price Target to $29
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Collegium Pharmaceutical, Inc.
Industry: Medical - Drugs
Company: Collegium Pharmaceutical, Inc.
Industry: Medical - Drugs
COVID-Related Mix Shift Worsened in 3Q; All Eyes Now On 2022 Guidance and Execution
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Collegium Pharmaceutical, Inc.
Industry: Medical - Drugs
Company: Collegium Pharmaceutical, Inc.
Industry: Medical - Drugs
Company: Collegium Pharmaceutical, Inc.
Industry: Medical - Drugs
2Q21: Worse Than Expected COVID Impact on Xtampza ER Economics Yields Lower Sales Guidance
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O